Skip to main content

Day: December 6, 2022

Brandywine Realty Trust Prices $350 Million of 7.550% Guaranteed Notes Due 2028

PHILADELPHIA, Dec. 06, 2022 (GLOBE NEWSWIRE) — Brandywine Realty Trust (the “Company”) (NYSE:BDN) announced today that its operating partnership, Brandywine Operating Partnership, L.P. (the “Operating Partnership”), has priced an underwritten public offering of $350 million of its 7.550% guaranteed notes due 2028 (the “Notes”). Interest on the Notes will be payable semi-annually on March 15 and September 15 of each year, commencing March 15, 2023. The Notes are being offered to investors at a price of 99.058% of their principal amount, plus accrued interest, if any, from December 13, 2022, with a re-offer yield of 7.776%. The sale of the Notes is expected to close on December 13, 2022, subject to customary closing conditions. The net proceeds of the offering, after deducting underwriting discounts and estimated transaction expenses...

Continue reading

X4 Pharmaceuticals Announces Proposed Public Offering

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and accompanying warrants to purchase shares of its common stock (or pre-funded warrants). In addition, X4 expects to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering will be sold by X4. The offering is subject to market and other conditions,...

Continue reading

Daktronics, Inc. Announces Date Change for Second Quarter Fiscal 2023 Financial Results

BROOKINGS, S.D., Dec. 06, 2022 (GLOBE NEWSWIRE) — Daktronics Inc (Nasdaq – DAKT) announced today that in light of the Company’s announcement in its Current Report on Form 8-K filed today with the Securities and Exchange Commission, it has changed the date and time of its previously announced earnings release and conference call and webcast for its second quarter fiscal 2023 financial results. The Company will now release the second quarter fiscal 2023 financial results on Monday, December 12, 2022, before the market opens. The Company will host a conference call and webcast for all interested parties at 10:00 AM CT that day. Reece A. Kurtenbach, Chief Executive Officer, and Sheila M. Anderson, Chief Financial Officer, will host the conference call, which will contain forward-looking statements and other material information. To...

Continue reading

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 – 8, 2022. In the completed Phase 2 study, MN-001 (tipelukast) significantly reduced serum triglycerides in participants with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia (HTG). Subsequent in vitro results revealed that MN-001 (tipelukast)...

Continue reading

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices

Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol “OSA” SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) —  ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. (“Lakeshore”) (Nasdaq: LAAA), a publicly traded special purpose acquisition company. ProSomnus will commence trading on the Nasdaq Global Market under the symbol “OSA” on Dec. 7, 2022. The business combination, which was approved by Lakeshore’s shareholders on Dec. 2, 2022, along with the convertible debt issued in connection with the transaction, provides access to capital that will be used to drive...

Continue reading

Great Southern Bancorp, Inc. Announces Fourth Quarter 2022 Preliminary Earnings Release Date and Conference Call

SPRINGFIELD, Mo., Dec. 06, 2022 (GLOBE NEWSWIRE) — Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, expects to report fourth quarter 2022 preliminary earnings after the market closes on Monday, January 23, 2023, and host a conference call on Tuesday, January 24, 2023, at 2:00 p.m. Central Time (3:00 p.m. Eastern Time). The call will be available live or later in a recorded version at the Company’s Investor Relations website, https://investors.greatsouthernbank.com. Participants may register for the call here. While not required, it is recommended that participants join 10 minutes prior to the event start. Instructions are provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these programs at no cost. The Company will notify the public that fourth...

Continue reading

TOP Ships Announces Closing of $13.5 Million Public Offering

ATHENS, Greece, Dec. 06, 2022 (GLOBE NEWSWIRE) — TOP Ships Inc. (NASDAQ: TOPS) (the “Company”), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today the closing of its previously announced public offering of 6,750,000 units at a price of $2.00 per unit. Each unit consisted of one common share and one Class C warrant to purchase one common share, which were immediately separated upon issuance. The gross proceeds of the offering to the Company, before discounts and commissions and estimated offering expenses, were approximately $13.5 million. Each Class C warrant is immediately exercisable for one common share at an exercise price of $2.00 per share and will expire five years from the date of issuance. Maxim Group LLC acted as the sole placement agent in connection with the...

Continue reading

Patriot Battery Metals Commences Trading on the ASX

VANCOUVER, British Columbia, Dec. 06, 2022 (GLOBE NEWSWIRE) — Patriot Battery Metals Inc. (the “Company” or “Patriot”) (TSX-V: PMET) (ASX: PMT) (OTCQB: PMETF) (FSE: R9GA) is pleased to announce that the securities of the Company will commence quotation at 12.00 PM Australia Eastern Daylight Time (AEDT) on Wednesday, 7 December 2022. The shares of Patriot Battery Metals will trade under the ticker PMT and will be settled in the form of CHESS Depositary Interests (‘CDIs’) at a ratio of 10 CDIs to 1 share. The Company raised AUD $4,200,000 pursuant to the offer under its prospectus dated 9 November 2022 by the issue of 7,000,000 CDIs at an issue price of AUD $0.60 per CDI. Blair Way, Company President, CEO and Director, comments: “It is great to be trading on the ASX. With the ASX listing blackout behind us I look forward to getting...

Continue reading

Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates

PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA). “This acquisition is a highly strategic move to enable us to achieve our aspirations to become a global leader and innovator of implant-based breast reconstruction (IBBR) procedures,” said Robert T. Davis, Jr., executive vice president and president, Tissue Technologies, Integra Life Sciences. “We are looking forward to working with SIA colleagues to continue pursuing our mission to improve patient outcomes.” About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians...

Continue reading

Targa Resources Corp. to Participate in Capital One Securities 17th Annual Energy Conference

HOUSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa” or the “Company”) announced today that representatives from the Company will participate in investor meetings at the Capital One Securities 17th Annual Energy Conference on Wednesday, December 7, 2022 in Houston, TX. A copy of the slides used for the conference meetings will be available in the Investors section of the Company’s website at www.targaresources.com, or by going to https://www.targaresources.com/investors/events. About Targa Resources Corp. Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent midstream infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary domestic midstream...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.